Amgen Inc.

Allstate Insurance Company

Array Biopharma Inc.

Kevin Chao Yang

Nobuko Nishimura

Shon Booker

Longbin Liu

Ning Chen

David John Kopecky

Mark Henry Norman

Julio Cesar Medina

Jonathan B Houze

Xiaohui Du

Xiaoqi Chen

Matthew R Kaller

Jeffrey Thomas Mihalic

Zhihua Ma

Zice Fu

Paul John Dransfield

Aaron C Siegmund

Vatee Pattaropong

Xiaodong Wang

Daniel B Horne

Richard V Connors

Julie Anne Heath

Jeffrey Deignan

Steven H Olson

Su-Jen Lai

Lawrence R McGee

Alan C Cheng

Mikkel V Debenedetto

Derin C D'amico

Christopher Michael Tegley

Ning Xi

Jian Jeffrey Chen

Nuria A Tamayo

Ted Charles Judd

Aiwen Li

Frank Kayser

Patricia Lopez

Thomas T Nguyen

Victor J Cee

Brian Alan Lanman

Tae-Seong Kim

Gayathri Swaminath

Jean-Christophe P Harmange

Anthony B Reed

Chester Chenguang Yuan

Wen-Chen Yeh

Qingyian Liu

Christopher Harold Fotsch

Alexander J Pickrell

Ryan Paul Wurz

Hui-Ling Wang

Steven F Bellon

Markian Myroslaw Stec

Nianhe Han

Julie Germain

Deborah Choquette

Michele Potashman

Brian K Albrecht

Scott S Harried

Vu Van Ma

Qi Huang

Wenyuan Qian

Alessandro Boezio

Benny C Askew

Kaustav Biswas

Jiawang Zhu

Celia Dominguez

Andrew Stewart Tasker

Gang Liu

Jennifer Rebecca Allen

Daniel Elbaum

Qiufen May Xue

Richard Thomas Lewis

Ana Elena Minatti

Albert Kudzovi Amegadzie

John Gordon Allen

Jonathan Dante Low

Laurie B Schenkel

Daniel La

Youngsook Shin

Russell Graceffa

Guoqing Paul Chen

Robert D Groneberg

Michael D Croghan

Adrian Leonard Smith

Joseph L Kim

Ben C Askew

Vinod Francis Patel

Bin Wu

Liping H Pettus

Guolin Cai

Lucian V DiPietro

David A Mareska

Michael D Bartberger

Lewis D Pennington

Stephanie Geuns-Meyer

Randall W Hungate

Daniel A Erlanson

Karina Romero

Jason Brooks Human

Methods and systems disclosed herein describe a universal access layer that allows a plurality of applications to obtain data and/or information from a plurality of heterogeneous data stores. The universal access layer may include one or more application data objects to validate requests, transform a format of the request, determine which data stores comprise the requested data and/or information, encrypt the request, combine responses into a single response, and retransform the response prior to sending it to the requesting application. By using the universal access layer, applications may improve the speed with which they access data and/or information from the plurality of heterogeneous data stores.

Universal access layer for accessing heterogeneous data stores

Methods and systems disclosed herein describe deploying a plurality of microservices to calculate an insurance rate. The plurality of microservices may operate in parallel to calculate a plurality of partial rates that are combined (e.g., added up) to determine the insurance rate. During the calculating steps, one or more rating factors may be cached and/or stored. The plurality of microservices may reduce the time and/or resources required by a processor to calculate an insurance rate, while the stored rating factors may be displayed to the user to provide greater transparency into how the insurance rate was calculated.

Distributed processing to provide transparency in rate determination

Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

Substituted piperazines as KRAS G12C inhibitors

Methods and systems disclosed herein describe a canonical model that sets forth a standardized schema that represents data entities and their relationships as a logical data structure across multiple business units. A schema validator module may validate application-specific schema against the canonical module. Additionally, legacy and/or existing applications may be upgraded, through a transformation module, to comply with the canonical model. The transformation module may transform application-specific data and/or information to the standardized schema, and vice versa, to ensure that legacy and/or existing applications may communicate with applications and/or processing engines that comply with the standardized schema.

Canonical model for product development

Provided herein are methods of treating cancer with KRAS G12C inhibitors of Formula I and compositions of the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers. 

KRAS G12C inhibitors and methods of using the same

Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heteroaryl-substituted triazoles as APJ receptor agonists

Provided herein are KRAS G12C inhibitors, compounds of formula (II), or a pharmaceutically acceptable salt thereof: compositions of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Triazole agonists of the APJ receptor

Compounds of Formula VII, salts thereof, tautomers thereof, and salts of the tautomers are useful intermediates in the synthesis of agonists of the APJ Receptor. Compounds of Formula VII have the following structure: where the definitions of the variables are provided herein.

Intermediates for preparing triazole agonists of the APJ receptor

Methods of preparing compounds of Formula VI, salts thereof, tautomers thereof, or salts of the tautomers include cyclizing compounds of Formula V, salts thereof, tautomers thereof, or salts of the tautomers. Compounds of Formula VI and Formula V have the following structures: where the definitions of the variables are provided herein.

Methods for preparing triazole agonists of the APJ receptor

Growing community of inventors

San Gabriel, CA, United States of America

Kevin Chao Yang